Next, to determine whether the AKT-mTORC1 pathway is involved in the IL-15-induced migration of tumor cells, we used the inhibitors LY294002 and rapamycin to inhibit AKT and mTORC1 activity, respectively. Here, IL15 is linked to neoplasm.